Clinical trial · Observational
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
Observatory for Patients Treated for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia With Oncogenetic Features.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to improve the outcome of relapsed and/or refractory T-cell precursor acute lymphoblastic leukemia (T-ALL) patients, and to facilitate the use of oncogenetic targeted therapies in these patients, we set up an observational cohort, collecting clinical and biological information's from patients with T-ALL in relapse or refractory, as well as the use or not of a targeted therapy. The analysis of the cohort will allow us to evaluate the impact of this therapeutic strategies on the patients' fate, and to facilitate access to innovation and personalized medicine for these patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Acute Lymphoblastic Leukemia | — | UNRESOLVED | — |
| T-cell Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response rate defined as complete remission and remission without complete hematological recovery (CR + CRi).
- timeFrame
- 3 months
- description
- Response rate defined as complete remission and remission without complete hematological recovery (CR + CRi).
Secondary outcomes (8)
- measure
- Performance Status of patients
- timeFrame
- 3 months
- description
- Eastern Cooperative Oncology Group (ECOG) - Performans Status Scale PS 0 : Fully active, able to carry on all pre-disease performance without restriction PS 4: Completely disabled; cannot carry on any selfcare; totally confined to bed or chair
- measure
- Biological description of T-ALL
- timeFrame
- 3 months
- description
- Phenotypic and oncogenetic characterization with mutated signaling pathways
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years of age or older * Patients with relapsed or refractory T-cell precursor ALL or T-cell lymphoblastic lymphoma * Oncogenetic analysis performed at diagnosis and/or relapse in the central laboratory Exclusion Criteria: * Patient who refuse to be registered
References
Publications (0)
Data not yet available